Company Profile
BridgeBio Stock Price, News & Catalysts
- Ticker:
- BBIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
81.50 USD (-1.74%)
Close
Last updated: August 21, 2026
12.5B USD
Market cap
Why the stock is moving
The latest monitored company update is “BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026.” The corresponding closing-price reaction is not yet available.
Company overview
Genetically Defined Diseases
BridgeBio Pharma develops medicines for genetic diseases and genetically driven cancers. Its decentralized portfolio model creates focused teams around individual disease programs.
Attruby
Attruby, or acoramidis, is an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy. It anchors BridgeBio's commercial rare-cardiovascular franchise.
BBP-418
BBP-418 is an oral substrate-supplementation therapy under FDA review for limb-girdle muscular dystrophy type 2I/R9.
Encaleret
Encaleret is an oral calcium-sensing-receptor antagonist being prepared for regulatory submission in autosomal dominant hypocalcemia type 1.
Infigratinib
Low-dose oral infigratinib targets FGFR3 signaling in achondroplasia and is advancing toward an NDA based on late-stage clinical development.
Future catalysts
- NDA submission for encaleret in autosomal dominant hypocalcemia type 1 in the first half of 2026.
- NDA submission for oral infigratinib in achondroplasia in the third quarter of 2026.
- FDA review milestones for the submitted BBP-418 application, including a potential Priority Review decision.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BridgeBio (BBIO)?
BridgeBio (BBIO) most recently closed at 81.50 USD, a -1.74% move versus the previous session.
What is the market cap of BridgeBio (BBIO)?
BridgeBio currently has a market capitalization of 12.5B USD on BioPharmSignal.
What does BridgeBio do?
Genetically Defined Diseases BridgeBio Pharma develops medicines for genetic diseases and genetically driven cancers. Its decentralized portfolio model creates focused teams around individual disease programs. Attruby Attruby, or acoramidis, is an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy. It anchors BridgeBio's...
On which exchange is BBIO stock listed?
BridgeBio (BBIO) is associated with NASDAQ, United States, Biopharma.
What is BBP-418?
FDA review milestones for the submitted BBP-418 application, including a potential Priority Review decision.
Which conditions is BridgeBio targeting with BBP-418?
BridgeBio is associated with cancer therapeutics, cardiovascular disease, genetic disease based on its company overview and current catalyst commentary.
How does BridgeBio describe recent progress with BBP-418?
FDA review milestones for the submitted BBP-418 application, including a potential Priority Review decision.
What is infigratinib?
Infigratinib Low-dose oral infigratinib targets FGFR3 signaling in achondroplasia and is advancing toward an NDA based on late-stage clinical development.